Journal
JOURNAL OF RHEUMATOLOGY
Volume 38, Issue 2, Pages 236-241Publisher
J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.100564
Keywords
RHEUMATOID ARTHRITIS; CARDIOVASCULAR DISEASES; HYPERTENSION; LEFLUNOMIDE; REMISSION INDUCTION
Categories
Ask authors/readers for more resources
Objective. To evaluate the incidence of cardiovascular disease (CVD) among Greek patients with rheumatoid arthritis (RA) under medical followup, and to assess the contribution of traditional CVD and RA-specific factors associated with CVD development. Methods. This is a historic cohort study; information was collected from medical records of patients who had > 2 years' followup. Sociodemographic, clinical, laboratory, and therapeutic variables were evaluated for association with development of CVD. Results. A total of 325 RA patients were studied: 250 women, mean age at RA onset 44 +/- 15 years, and 75 men, mean age at RA onset 51 +/- 15 years; median followup was 10 years. Fourteen women (5.6%) and 12 men (16%) developed CVD (p = 0.004). Multi-adjusted analysis revealed that hypertension (hazard ratio 3.76, 95% CI 0.99-15.06) was associated with incidence of CVD; late age at disease onset (HR 1.07, 95% CI 1.04-1.11), elevated C-reactive protein (CRP) level 1 year after start of followup (HR 1.03, 95% CI 1.00-1.05), and leflunomide treatment (HR per 1 year of treatment = 1.02, 95% CI 1.00-1.05) were also positively associated with CVD development. Conclusion. Hypertension was an important risk factor for CVD development in patients with RA. Late RA onset and inadequate early control of disease activity (as attested by CRP) remain additional risk factors. Leflunomide treatment may have a contributing effect. Early and effective treatment of RA and strict control of hypertension may modify the burden of CVD in RA patients. (J Rheumatol First Release Nov 15 2010; doi: 10.3899/jrheum.100564)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available